The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain

Anesthesia and Analgesia

Volumn 112, Issue 3, 2011, Pages 693-702

  Ashburn, Michael A ^a   Slevin, Kieran A ^a   Messina, John ^b   Xie, Fang ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; DEXTROPROPOXYPHENE; FENTANYL; FENTANYL CITRATE; HYDROCODONE; HYDROMORPHONE; LEVORPHANOL; METHADONE; MORPHINE; OPIATE DERIVATIVE; OXYCODONE; OXYMORPHONE; PLACEBO; SUFENTANIL CITRATE; TRAMADOL;

ADULT; ANALGESIC ACTIVITY; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; APPLICATION SITE ULCER; ARTICLE; BREAKTHROUGH PAIN; CHRONIC PAIN; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FEVER; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PAIN ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TABLET;

EID: 79952448795     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e318209d320     Document Type: Article

References (35)

1. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C, American Pain Society\American Academy of Pain Medicine Opi-oids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
2. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81 (Pubitemid 20187930)
3. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteris-tics and impact in patients with cancer pain. Pain 1999;81:129-34 (Pubitemid 29199908)
4. Svendsen KB, Andersen S, Arnason S, Arner S, Breivik H, Heiskanen T, Kalso E, Kongsgaard UE, Sjogren P, Strang P, Bach FW, Jensen TS. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005;9:195-206 (Pubitemid 40311842)
5. Zeppetella G, O'Doherty CA, Collins S. Prevalence and char-acteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000;20:87-92
6. Portenoy RK, Bennett DS, Rauck R, Simon S, Taylor D, Brennan M, Shoemaker S. Prevalence and characteristics of break-through pain in opioid-treated patients with chronic noncancer pain. J Pain 2006;7:583-91 (Pubitemid 44137488)
7. Taylor DR, Webster LR, Chun SY, Reinking J, Stegman M, Shoemaker S, Fortner B. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med 2007;8:281-8 (Pubitemid 46443468)
8. Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, Ripamonti C, De Conno F. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002;94:832-9 (Pubitemid 34132314)
9. Messina J, Darwish M, Fine PG. Fentanyl buccal tablet. Drugs Today (Barc) 2008;44:41-54 (Pubitemid 351397412)
10. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003;101:55-64 (Pubitemid 36044654)
11. Bennett D, Burton AW, Fishman S, Fortner B, McCarberg B, Miaskowski C, Nash D, Pappagallo M, Payne R, Ray J, Viscusi E, Wong W. Consensus panel recommendations for the assess-ment and management of breakthrough pain. Part 2. Manage-ment. P&T 2005;30:354-61 (Pubitemid 40885216)
12. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91:123-30 (Pubitemid 32274181)
13. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10:147-59
14. Fentora [package insert]. Frazer, PA: Cephalon, Inc., December 2009
15. Darwish M, Kirby M, Robertson P Jr., Tracewell W, Jiang JG. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007;47:343-50 (Pubitemid 46294716)
16. Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am J Drug Deliv 2006;4:1-5
17. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1998;1:15-30
18. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805-11 (Pubitemid 44627444)
19. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5:327-34 (Pubitemid 350055013)
20. Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin 2007;23:223-33 (Pubitemid 46191684)
21. Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:588-601 (Pubitemid 47016640)
22. Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer 2009;11:2571-9
23. Fine PG, Messina J, Xie F, Rathmell J. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of break-through pain in opioid-tolerant patients with chronic pain: an 18-month study. J Pain Symptom Manage 2010;40:747-60
24. International Conference on Harmonisation Working group. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1). International Conference on Har-monisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; June 10, 1996; Washington, DC 1996. Available at: http://www.ich.org/LOB/media/MEDIA482.pdf. Last accessed: March 25, 2010
25. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianal-gesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manage 2001;22:672-87 (Pubitemid 32725810)
26. Anderson R, Saiers JH, Abram S, Schlicht C. Accuracy in equianalgesic dosing. Conversion dilemmas. J Pain Symptom Manage 2001;21:397-406 (Pubitemid 32452140)
27. Derby S, Chin J, Portenoy RK. Systemic opioid therapy for chronic cancer pain: practical guidelines for converting drugs and routes of administration. CNS Drugs 1998;9:99-109 (Pubitemid 28101533)
28. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, Mc-Quay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21 (Pubitemid 351147828)
29. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287-94
30. Liang KY, Zeger SL. Longitudinal data analysis using gener-alized linear models. Biometrika 1986;73:13-22
31. Hanley JA, Negassa A, Edwardes MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equa-tions: an orientation. Am J Epidemiol 2003;157:364-75 (Pubitemid 36196757)
32. Saunders DL, Messina J, Golsorkhi A, Leary KJ, Cantilena LR. Relative potency of fentanyl buccal tablet (100 and 400 mcg) to intravenous morphine (2 and 8 mg) in healthy volunteers undergoing thermally-induced hyperalgesia [abstract PIII-44]. Clin Pharmacol Ther 2009;85(suppl. 1):S82
33. Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, Frigerio V, Ingham J, Loseth DB, Nordbrock E, Rhiner M. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titra-tion study. Pain 1999;79:303-12 (Pubitemid 29076765)
34. Payne R, Coluzzi P, Hart L, Simmonds M, Lyss A, Rauck R, Berris R, Busch MA, Nordbrook E, Loseth DB, Portenoy RK. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001;22:575-83 (Pubitemid 32547445)
35. Hanks GW, Nugent M, Higgs CM, Busch MA. Oral transmu-cosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Palliat Med 2004;18:698-704 (Pubitemid 39654548)